Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 22 studies | 38% ± 14% | |
astrocyte | 16 studies | 44% ± 20% | |
microglial cell | 13 studies | 48% ± 15% | |
glutamatergic neuron | 12 studies | 49% ± 26% | |
fibroblast | 12 studies | 34% ± 13% | |
mast cell | 12 studies | 33% ± 10% | |
GABAergic neuron | 11 studies | 47% ± 27% | |
oligodendrocyte precursor cell | 11 studies | 47% ± 21% | |
oligodendrocyte | 10 studies | 34% ± 13% | |
pericyte | 9 studies | 25% ± 11% | |
adipocyte | 9 studies | 30% ± 9% | |
macrophage | 9 studies | 44% ± 17% | |
smooth muscle cell | 8 studies | 31% ± 6% | |
myeloid cell | 7 studies | 31% ± 12% | |
epithelial cell | 7 studies | 40% ± 19% | |
dendritic cell | 7 studies | 29% ± 7% | |
ciliated cell | 7 studies | 28% ± 11% | |
natural killer cell | 7 studies | 24% ± 5% | |
endothelial cell of lymphatic vessel | 7 studies | 44% ± 10% | |
regulatory T cell | 6 studies | 21% ± 5% | |
T cell | 6 studies | 27% ± 6% | |
neuron | 5 studies | 47% ± 23% | |
retinal ganglion cell | 5 studies | 32% ± 16% | |
amacrine cell | 5 studies | 34% ± 14% | |
B cell | 5 studies | 24% ± 8% | |
CD8-positive, alpha-beta T cell | 5 studies | 24% ± 6% | |
cardiac muscle cell | 5 studies | 46% ± 11% | |
type I pneumocyte | 5 studies | 28% ± 7% | |
type II pneumocyte | 5 studies | 38% ± 8% | |
monocyte | 5 studies | 33% ± 7% | |
basal cell | 5 studies | 37% ± 21% | |
interneuron | 5 studies | 61% ± 27% | |
non-classical monocyte | 4 studies | 20% ± 3% | |
mesothelial cell | 4 studies | 35% ± 8% | |
lymphocyte | 4 studies | 34% ± 16% | |
Mueller cell | 4 studies | 37% ± 12% | |
retina horizontal cell | 4 studies | 28% ± 6% | |
retinal cone cell | 4 studies | 37% ± 10% | |
retinal rod cell | 4 studies | 40% ± 10% | |
club cell | 4 studies | 32% ± 9% | |
CD16-negative, CD56-bright natural killer cell, human | 3 studies | 22% ± 3% | |
classical monocyte | 3 studies | 22% ± 6% | |
hematopoietic precursor cell | 3 studies | 21% ± 3% | |
plasma cell | 3 studies | 22% ± 5% | |
CD4-positive, alpha-beta T cell | 3 studies | 27% ± 3% | |
effector memory CD8-positive, alpha-beta T cell | 3 studies | 24% ± 5% | |
mononuclear phagocyte | 3 studies | 24% ± 3% | |
vein endothelial cell | 3 studies | 43% ± 23% | |
GABAergic amacrine cell | 3 studies | 34% ± 10% | |
glycinergic amacrine cell | 3 studies | 33% ± 7% | |
endothelial cell of vascular tree | 3 studies | 47% ± 22% | |
retinal pigment epithelial cell | 3 studies | 47% ± 22% | |
muscle cell | 3 studies | 44% ± 21% | |
abnormal cell | 3 studies | 31% ± 18% | |
ependymal cell | 3 studies | 45% ± 15% | |
megakaryocyte-erythroid progenitor cell | 3 studies | 32% ± 7% | |
respiratory goblet cell | 3 studies | 40% ± 14% | |
alveolar macrophage | 3 studies | 36% ± 8% | |
capillary endothelial cell | 3 studies | 29% ± 5% | |
granule cell | 3 studies | 40% ± 17% | |
leukocyte | 3 studies | 43% ± 5% | |
kidney loop of Henle epithelial cell | 3 studies | 41% ± 20% | |
renal principal cell | 3 studies | 48% ± 18% | |
mural cell | 3 studies | 40% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 27212.93 | 258 / 258 | 100% | 48.30 | 230 / 230 |
esophagus | 100% | 1697.87 | 1445 / 1445 | 100% | 25.58 | 183 / 183 |
lung | 100% | 1606.41 | 578 / 578 | 100% | 29.47 | 1155 / 1155 |
prostate | 100% | 1732.00 | 245 / 245 | 100% | 33.62 | 502 / 502 |
thymus | 100% | 1475.88 | 653 / 653 | 100% | 31.75 | 604 / 605 |
intestine | 100% | 1609.06 | 966 / 966 | 100% | 26.87 | 526 / 527 |
bladder | 100% | 2005.38 | 21 / 21 | 100% | 29.93 | 503 / 504 |
uterus | 100% | 2085.04 | 170 / 170 | 100% | 34.80 | 458 / 459 |
ovary | 100% | 2101.56 | 180 / 180 | 100% | 40.61 | 429 / 430 |
skin | 100% | 1668.77 | 1808 / 1809 | 100% | 34.10 | 471 / 472 |
breast | 100% | 1785.25 | 459 / 459 | 100% | 34.01 | 1115 / 1118 |
kidney | 100% | 2820.40 | 89 / 89 | 100% | 44.17 | 898 / 901 |
brain | 100% | 1315.80 | 2633 / 2642 | 100% | 31.92 | 705 / 705 |
stomach | 100% | 1264.06 | 359 / 359 | 100% | 26.17 | 285 / 286 |
liver | 100% | 1003.62 | 225 / 226 | 100% | 23.14 | 406 / 406 |
pancreas | 98% | 772.50 | 323 / 328 | 100% | 29.98 | 178 / 178 |
adipose | 100% | 1836.78 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2202.65 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 50.49 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 36.81 | 29 / 29 |
muscle | 100% | 2659.34 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 1906.00 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 24.00 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 16.41 | 1 / 1 |
peripheral blood | 99% | 1650.22 | 922 / 929 | 0% | 0 | 0 / 0 |
heart | 99% | 2184.34 | 849 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006325 | Biological process | chromatin organization |
GO_0010212 | Biological process | response to ionizing radiation |
GO_0045739 | Biological process | positive regulation of DNA repair |
GO_0006302 | Biological process | double-strand break repair |
GO_0007165 | Biological process | signal transduction |
GO_0006282 | Biological process | regulation of DNA repair |
GO_0006974 | Biological process | DNA damage response |
GO_0051301 | Biological process | cell division |
GO_0007095 | Biological process | mitotic G2 DNA damage checkpoint signaling |
GO_0044818 | Biological process | mitotic G2/M transition checkpoint |
GO_0070536 | Biological process | protein K63-linked deubiquitination |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0006915 | Biological process | apoptotic process |
GO_2000001 | Biological process | regulation of DNA damage checkpoint |
GO_0071479 | Biological process | cellular response to ionizing radiation |
GO_0005634 | Cellular component | nucleus |
GO_0005654 | Cellular component | nucleoplasm |
GO_0070531 | Cellular component | BRCA1-A complex |
GO_0070552 | Cellular component | BRISC complex |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0000152 | Cellular component | nuclear ubiquitin ligase complex |
GO_0000268 | Molecular function | peroxisome targeting sequence binding |
GO_0005164 | Molecular function | tumor necrosis factor receptor binding |
GO_0031593 | Molecular function | polyubiquitin modification-dependent protein binding |
GO_0005515 | Molecular function | protein binding |
Gene name | BABAM2 |
Protein name | Upstream ORF Alternative protein BRE BRISC and BRCA1-A complex member 2 (BRCA1-A complex subunit BRE) (BRCA1/BRCA2-containing complex subunit 45) (Brain and reproductive organ-expressed protein) BRISC and BRCA1-A complex member 2 |
Synonyms | BRCC45 BRE |
Description | FUNCTION: Component of the BRCA1-A complex, a complex that specifically recognizes 'Lys-63'-linked ubiquitinated histones H2A and H2AX at DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites of DNA damage at double-strand breaks (DSBs). The BRCA1-A complex also possesses deubiquitinase activity that specifically removes 'Lys-63'-linked ubiquitin on histones H2A and H2AX . In the BRCA1-A complex, it acts as an adapter that bridges the interaction between BABAM1/NBA1 and the rest of the complex, thereby being required for the complex integrity and modulating the E3 ubiquitin ligase activity of the BRCA1-BARD1 heterodimer . Component of the BRISC complex, a multiprotein complex that specifically cleaves 'Lys-63'-linked ubiquitin in various substrates . Within the BRISC complex, acts as an adapter that bridges the interaction between BABAM1/NBA1 and the rest of the complex, thereby being required for the complex integrity . The BRISC complex is required for normal mitotic spindle assembly and microtubule attachment to kinetochores via its role in deubiquitinating NUMA1 . The BRISC complex plays a role in interferon signaling via its role in the deubiquitination of the interferon receptor IFNAR1; deubiquitination increases IFNAR1 activity by enhancing its stability and cell surface expression . Down-regulates the response to bacterial lipopolysaccharide (LPS) via its role in IFNAR1 deubiquitination . May play a role in homeostasis or cellular differentiation in cells of neural, epithelial and germline origins. May also act as a death receptor-associated anti-apoptotic protein, which inhibits the mitochondrial apoptotic pathway. May regulate TNF-alpha signaling through its interactions with TNFRSF1A; however these effects may be indirect . . FUNCTION: May play a role in homeostasis or cellular differentiation in cells of neural, epithelial and germline origins. May also act as a death receptor-associated anti-apoptotic protein, which inhibits the mitochondrial apoptotic pathway. . FUNCTION: May play a role in homeostasis or cellular differentiation in cells of neural, epithelial and germline origins. May also act as a death receptor-associated anti-apoptotic protein, which inhibits the mitochondrial apoptotic pathway. . FUNCTION: May play a role in homeostasis or cellular differentiation in cells of neural, epithelial and germline origins. May also act as a death receptor-associated anti-apoptotic protein, which inhibits the mitochondrial apoptotic pathway. . |
Accessions | ENST00000344773.6 [Q9NXR7-1] Q9NXR7 ENST00000379629.7 F8W733 A0A075B7D2 ENST00000342045.6 [Q9NXR7-2] C9J2G0 ENST00000604932.1 Q96P08 L8E9D4 ENST00000436924.5 ENST00000379624.6 [Q9NXR7-2] ENST00000361704.6 [Q9NXR7-4] ENST00000379632.6 [Q9NXR7-4] |